Merck & Co., Inc. has reached an agreement with the ADAP Crisis Task Force intended to help state AIDS Drug Assistance Programs provide IDVYNSO, the once-daily combination of doravirine and islatravir, to eligible adults living with HIV-1. The arrangement follows the April 2026 United States approval of IDVYNSO as a two-drug, single-tablet switch regimen for certain adults whose virus is already suppressed on stable antiretroviral therapy.
The announcement moves IDVYNSO from regulatory availability toward practical access within one of the most important safety-net channels in United States HIV care. That distinction matters because approval establishes that a medicine may be prescribed, while pricing agreements, state formularies, eligibility rules and pharmacy infrastructure determine whether underserved patients can actually receive it.
Why the IDVYNSO agreement matters more than a routine post-approval access arrangement
AIDS Drug Assistance Programs provide medications, insurance support and treatment-related services to low-income people living with HIV who have limited or no adequate coverage. In calendar 2024, these state and territorial programmes served nearly 258,000 clients, making them a major route through which newly approved antiretroviral medicines can reach populations that might otherwise face financial or administrative barriers.
The scale of the system gives Merck’s agreement commercial and public-health relevance, but the larger issue is the financial condition of the programmes themselves. Federal funding earmarked for AIDS Drug Assistance Programs remained broadly flat in fiscal 2024 even as enrolment rose, forcing programmes to rely heavily on rebates, supplemental discounts and other revenue generated through the 340B Drug Pricing Program. Rebates represented more than half of the overall AIDS Drug Assistance Program budget during the period.
A negotiated arrangement can therefore influence more than the acquisition cost of one medicine. Lower net pricing may help programmes add IDVYNSO without removing other therapies, narrowing eligibility or imposing burdensome utilisation controls. It may also reduce the trade-off between funding medicines and supporting related services such as adherence programmes, insurance premiums and clinical monitoring.
The agreement does not, however, create a national entitlement to IDVYNSO. Each state or territory retains authority over eligibility, formulary design and distribution, meaning access may still vary geographically. Merck has opened an important door, but state-level implementation will determine how many patients ultimately walk through it.
How a confidential pricing agreement could influence state ADAP formulary decisions
The ADAP Crisis Task Force negotiates voluntary supplemental discounts and rebate arrangements with pharmaceutical manufacturers on behalf of programmes across the United States and its territories. Such negotiations are intended to obtain better net prices than programmes could secure individually, while reducing the need for delayed formulary additions, prior authorisation or other cost-containment measures.
The financial terms of the IDVYNSO agreement have not been disclosed, consistent with the confidentiality surrounding these arrangements. The absence of public pricing prevents an external assessment of whether Merck has offered a sufficiently strong discount to alter prescribing access or whether the deal mainly establishes a framework for future purchasing.
For state programmes, the decision will not depend on discount size alone. Administrators must consider the number of eligible clients, expected prescribing demand, rebate timing, pharmacy contracts, resistance-testing requirements and the cost of monitoring patients who switch from established regimens. Even a competitively priced therapy can be slow to gain traction when programmes face staffing shortages, fragmented data systems or delayed manufacturer rebate payments.
Those operational pressures are not theoretical. Many programmes have reported difficulties maintaining client eligibility, exchanging information across health systems and receiving rebates promptly. A new agreement can improve the economics of access, but it cannot independently repair the administrative machinery required to deliver that access consistently.
IDVYNSO may nevertheless be easier to integrate than provider-administered therapies because it is an oral, once-daily tablet distributed through conventional pharmacy channels. Long-acting injectable HIV treatments can require medical-benefit billing, clinic appointments and administration-cost coverage, capabilities that remain uneven across state programmes. IDVYNSO avoids those particular obstacles, although it still requires careful patient selection.
Where IDVYNSO fits in an HIV market already crowded with effective switch options
IDVYNSO enters a treatment market in which virologically suppressed adults already have several highly effective options. These include three-drug, integrase inhibitor-based single-tablet regimens such as bictegravir, emtricitabine and tenofovir alafenamide, as well as two-drug products built around dolutegravir or rilpivirine. Long-acting cabotegravir and rilpivirine injections have also expanded the range of maintenance strategies available to eligible patients.
Merck is therefore not filling an absence of effective therapy. IDVYNSO instead offers a differentiated switch option for adults who may benefit from avoiding an integrase strand transfer inhibitor, tenofovir or a three-drug regimen. Doravirine is a non-nucleoside reverse transcriptase inhibitor, while islatravir is a nucleoside analogue reverse transcriptase inhibitor with multiple mechanisms intended to interrupt HIV replication.
That non-integrase positioning may be relevant when clinicians are reviewing tolerability, metabolic concerns, comorbidities, previous treatment exposure or potential drug interactions. The tenofovir-free design may also interest clinicians managing patients for whom renal or bone considerations influence regimen selection. These potential advantages do not mean IDVYNSO is inherently preferable to established treatments, since individual treatment history and resistance remain decisive.
Its two-drug composition may appeal to patients and clinicians seeking regimen simplification, but pill count alone is unlikely to determine adoption. Many competing regimens are also delivered as one tablet daily, and some have broader indications or longer real-world experience. IDVYNSO must therefore compete through its pharmacological profile and suitability for particular patients rather than through convenience alone.
The approved United States indication is also narrower than a general first-line treatment label. IDVYNSO is approved to replace an existing regimen in virologically suppressed adults who have no history of virologic treatment failure and no known substitutions associated with doravirine resistance. That makes it a targeted maintenance option rather than a universal entry point into treatment.
Why the Phase 3 evidence supports access while still leaving selection questions open
The approval was supported by two randomised, active-controlled Phase 3 switch trials involving adults whose HIV-1 was already suppressed. Trial 052 compared a switch to IDVYNSO with continued bictegravir, emtricitabine and tenofovir alafenamide, while Trial 051 compared IDVYNSO with a range of baseline oral antiretroviral regimens.
At Week 48 in Trial 052, approximately 1% of participants in each treatment group had HIV-1 RNA of at least 50 copies per millilitre. Viral suppression below that threshold was maintained by 92% of participants receiving IDVYNSO and 94% of those continuing the comparator regimen. In Trial 051, approximately 1% of participants receiving IDVYNSO and 5% remaining on baseline therapy had HIV-1 RNA at or above 50 copies per millilitre, while suppression was maintained by 96% and 92%, respectively.
The studies established non-inferiority, which supports IDVYNSO as an effective switch strategy but should not be interpreted as proof of superiority over the comparators. Trial 052 used a double-blind design against a widely used benchmark regimen, strengthening the comparative evidence. Trial 051 broadened the evidence across different baseline therapies, although its open-label design creates more potential for behavioural and reporting effects.
Longer follow-up through Week 96 has shown sustained viral suppression without a newly identified safety pattern, giving clinicians more confidence than a Week 48 dataset alone. Real-world evidence will still be important because trial participants were selected for stable suppression, treatment reliability and the absence of relevant resistance or previous virologic failure.
The trials also excluded participants with active hepatitis B virus infection. That limitation matters because IDVYNSO does not provide hepatitis B treatment activity. Patients moving from tenofovir-containing regimens may require continued hepatitis B-active therapy or an alternative strategy when coinfection is present, reducing the simplicity of the switch for this subgroup.
Which clinical and operational limits could slow broader adoption across state programmes
Resistance history is likely to be one of the most important practical filters. IDVYNSO is not intended for adults with previous virologic treatment failure or known doravirine-associated resistance substitutions. Clinicians must therefore review historical regimens, laboratory records and resistance tests before switching, a process that can be difficult when patients have received care across multiple systems.
Drug interactions create another boundary. Strong cytochrome P450 3A inducers can lower doravirine exposure and reduce treatment effectiveness. IDVYNSO is also contraindicated with lamivudine or emtricitabine because those medicines may reduce exposure to the active form of islatravir. These restrictions require comprehensive medication reconciliation, particularly among older adults managing several chronic conditions.
The label includes warnings for severe skin and hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis and drug rash with eosinophilia and systemic symptoms. A severe case of immune thrombocytopenia occurred in the clinical programme, although no broader pattern of platelet decline emerged across the trials. Common adverse reactions were generally infrequent and included diarrhoea, dizziness, fatigue, abdominal distension, headache and weight increase.
IDVYNSO is not recommended for patients with an estimated glomerular filtration rate below 30 millilitres per minute per 1.73 square metres, and clinical information remains limited in pregnancy and severe hepatic impairment. These factors will restrict use in some medically complex patients, even when avoidance of tenofovir or an integrase inhibitor appears attractive.
State programme adoption may also depend on how easily prescribers understand the eligible population. A medicine positioned as a selective alternative can be clinically useful but commercially slower to establish than a broad default regimen. Merck will need to support accurate identification of appropriate candidates without creating an impression that simplification automatically justifies switching a patient who is stable and tolerating current therapy.
What Merck and HIV access stakeholders will need to demonstrate after the agreement
The first measure of the agreement’s value will be the speed at which state formularies add IDVYNSO and whether programmes impose prior authorisation or other restrictions. Broad formulary availability would show that the negotiated economics are workable. Delayed or inconsistent listings would suggest that pricing, budget pressure or clinical positioning remains a barrier.
The second measure will be whether access reaches patients most likely to benefit from an alternative to integrase inhibitor-based or tenofovir-containing therapy. Total prescription volume alone will not reveal whether the agreement is improving care for underserved populations or merely shifting patients among already accessible regimens.
Real-world persistence, virologic control, resistance outcomes and discontinuation rates will also shape confidence. Trial evidence supports efficacy in carefully selected suppressed adults, but programme populations may have more complex treatment histories, unstable insurance coverage and greater administrative disruption. Those differences can expose implementation risks that controlled studies are not designed to measure.
For Merck, the agreement provides an opportunity to establish IDVYNSO within the United States HIV treatment infrastructure soon after approval. It also supports a broader islatravir strategy that includes investigational weekly treatment combinations and monthly oral prevention programmes. Successful access to the daily regimen could strengthen familiarity with the molecule, but setbacks involving tolerability, resistance selection or uneven reimbursement would affect confidence across the wider franchise.
The agreement is therefore meaningful without being transformative on its own. It addresses one of the essential conditions for adoption, an economically viable route into the safety net. The remaining test is whether state programmes, clinicians and patients find that IDVYNSO offers enough clinical value to justify a switch from therapies that are already suppressing the virus effectively.
Can Merck’s IDVYNSO agreement widen HIV treatment access across state programmes? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →